Amalgamated Bank Fate Therapeutics Inc Transaction History
Amalgamated Bank
- $13.6 Billion
- Q3 2025
A detailed history of Amalgamated Bank transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Amalgamated Bank holds 2,912 shares of FATE stock, worth $2,882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,912
Previous 2,912
-0.0%
Holding current value
$2,882
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FATE
# of Institutions
157Shares Held
80.1MCall Options Held
159KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.7 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$10 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.8MShares$8.71 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.5 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.35 Million1.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $96M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...